Research advances in mechanism of the role of ischemia-reperfusion injury in promoting recurrence of hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-3232.2024.01.019

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Surgical resection, liver transplantation and other surgical regimens remain the most effective treatments for HCC. To prevent the intraoperative bleeding, it is necessary to occlude the blood supply at the hilum during most HCC surgeries. Ischemia-reperfusion injury (IRI) caused by blood flow occlusion is intimately associated with the recurrence of HCC. The effect of IRI on postoperative recurrence of HCC is mainly correlated with reactive oxygen species, inflammatory cytokines, nitric oxide, heat shock protein, ferroptosis, Kupffer cells and protease, etc.

Key words: Carcinoma, hepatocellular, Recurrence, Ischemia-reperfusion injury, Reactive oxygen species, Free radical, Inflammatory factor, Heat shock protein, Ferroptosis, Intestinal liver axis

Yabo Shi, Yang Li, Changwen Huang. Research advances in mechanism of the role of ischemia-reperfusion injury in promoting recurrence of hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 96-99.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.01.019

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I01/96

References 37

[1]	Wang D, Zheng X, Fu B, et al. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling[J]. EBioMedicine, 2019(46):119-132.
[2]	Chen H, Lu D, Yang X, et al. One shoot, two birds: alleviating inflammation caused by ischemia/reperfusion injury to reduce the recurrence of hepatocellular carcinoma[J]. Front Immunol, 2022(13):879552.
[3]	Cannito S, Turato C, Paternostro C, et al. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells[J]. Oncotarget, 2015, 6(4):2206-2221.
[4]	Mu H, Yu G, Li H, et al. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation[J]. Cell Oncol, 2021, 44(5):1151-1166.
[5]	Turato C, Vairetti M, Cagna M, et al. SerpinB3 administration protects liver against ischemia-reperfusion injury[J]. Eur J Histochem, 2022, 66(4):3561.
[6]	Kung-Chun Chiu D, Pui-Wah Tse A, Law C T, et al. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway[J]. Cell Death Dis, 2019, 10(12):934.
[7]	Chang H, Li J, Qu K, et al. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NF-κB pathway in hepatocellular carcinoma[J]. Cell Death Dis, 2020, 11(5):332.
[8]	Luis G, Godfroid A, Nishiumi S, et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence[J]. Redox Biol, 2021(43):102006.
[9]	Matsumoto K, Satoh Y, Sugo H, et al. Immunohistochemical study of the relationship between 8-hydroxy-2'-deoxyguanosine levels in noncancerous region and postoperative recurrence of hepatocellular carcinoma in remnant liver[J]. Hepatol Res, 2003, 25(4):435-441.
[10]	Yugawa K, Itoh S, Yoshizumi T, et al. Prognostic impact of 8-hydroxy-deoxyguanosine and its repair enzyme 8-hydroxy-deoxyguanosine DNA glycosylase in hepatocellular carcinoma[J]. Pathol Int, 2020, 70(8):533-541.
[11]	Pang L, Yeung OWH, Ng KTP, et al. Postoperative plasmacytoid dendritic cells secrete IFNα to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence[J]. Cancer Res, 2022, 82(22):4206-4218.
[12]	陶璇, 王斌, 陈虹, 等. 肝细胞癌中精氨酸酶1和诱导型一氧化氮合成酶表达的临床意义及其相关性研究[J]. 中华肝脏病杂志, 2020, 28(11):924-929.
[13]	Sun MH, Han XC, Jia MK, et al. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma[J]. World J Gastroenterol, 2005, 11(38):5931-5937.
[14]	Yu H, Lin L, Zhang Z, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study[J]. Signal Transduct Target Ther, 2020, 5(1):209.
[15]	Yokoo H, Yasuda J, Nakanishi K, et al. Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinoma[J]. Hepatol Res, 2011, 41(3):240-249.
[16]	Pocino K, Stefanile A, Basile V, et al. Cytokines and hepatocellular carcinoma: biomarkers of a deadly embrace[J]. J Pers Med, 2022, 13(1):5.
[17]	Iwahasi S, Rui F, Morine Y, et al. Hepatic stellate cells contribute to the tumor malignancy of hepatocellular carcinoma through the IL-6 pathway[J]. Anticancer Res, 2020, 40(2):743-749.
[18]	皮丽娜, 候艳莹, 张维. 肠道菌群失调、炎症因子变化、维生素缺乏与肝癌患者根治术后复发的关系[J]. 现代肿瘤医学, 2019, 27(17):3078-3081.
[19]	Zhang M, Zhang S, Yang Z, et al. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence[J]. Oncol Lett, 2018, 16(6):7158-7165.
[20]	Yang Z, Zhuang L, Szatmary P, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma[J]. Int J Med Sci, 2015, 12(3):256-263.
[21]	刘金钢, 李岩, 刘丹, 等. HSP70与PI3K/Akt信号通路在肝细胞肝癌组织中的表达及意义[J/OL]. 中华肝脏外科手术学电子杂志, 2013, 2(1):45-52.
[22]	Yang S, Xiao H, Cao L. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment[J]. Biomed Pharmacother, 2021(142):112074.
[23]	Cho W, Jin X, Pang J, et al. The molecular chaperone heat shock protein 70 controls liver cancer initiation and progression by regulating adaptive DNA damage and mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathways[J]. Mol Cell Biol, 2019, 39(9):e00391-18.
[24]	Wang Q, Wang K, Tan X, et al. Immunomodulatory role of metalloproteases in cancers: current progress and future trends[J]. Front Immunol, 2022(13): 1064033.
[25]	Hwang KE, Kim HJ, Song IS, et al. Salinomycin suppresses TGF-β1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer[J]. Int J Med Sci, 2021, 18(3):715-726.
[26]	Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3):212-226.
[27]	Cabral-Pacheco GA, Garza-Veloz I, Castruita-De La Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases[J]. Int J Mol Sci, 2020, 21(24):9739.
[28]	Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: deciphering the role of gut microbiome[J]. Adv Cancer Res, 2021(149):171-255.
[29]	付豪爽, 赵爽, 谢青. 肠道菌群促进肝癌发生的机制及其临床应用[J]. 肝脏, 2021, 26(6):696-700.
[30]	Bartolini I, Risaliti M, Tucci R, et al. Gut microbiota and immune system in liver cancer: promising therapeutic implication from development to treatment[J]. World J Gastrointest Oncol, 2021, 13(11):1616-1631.
[31]	Zhang C, Yang M, Ericsson AC. The potential gut microbiota-mediated treatment options for liver cancer[J]. Front Oncol, 2020(10):524205.
[32]	Shen S, Khatiwada S, Behary J, et al. Modulation of the gut microbiome to improve clinical outcomes in hepatocellular carcinoma[J]. Cancers, 2022, 14(9):2099.
[33]	Spanu D, Pretta A, Lai E, et al. Hepatocellular carcinoma and microbiota: implications for clinical management and treatment[J]. World J Hepatol, 2022, 14(7):1319-1332.
[34]	Torti SV, Manz DH, Paul BT, et al. Iron and cancer[J]. Annu Rev Nutr, 2018(38):97-125.
[35]	Toyokuni S, Ito F, Yamashita K, et al. Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis[J]. Free Radic Biol Med, 2017(108):610-626.
[36]	Kim SE, Zhang L, Ma K, et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth[J]. Nat Nanotechnol, 2016, 11(11):977-985.
[37]	Wu J, Wang Y, Jiang R, et al. Ferroptosis in liver disease: new insights into disease mechanisms[J]. Cell Death Discov, 2021, 7(1):276.

Please choose a citation manager

Content to export